UNBELIEVABLE: Crispr rapeutics - The Untold Story

Here are the 5 biggest innovations to expect in 2023

Inverse predicts the biggest innovations of 2023, including wins in renewable energy, electric vehicles, and biotechnology.

Inverse · Jan 5, 2023

Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2022

 

Benzinga · Aug 9, 2022

CRISPR, 10 Years On: Learning to Rewrite the Code of Life

Ten years ago this week, Jennifer Doudna and her colleagues published the results of a test-tube experiment on bacterial genes. When the study came out in the journal Science on June 28, 2012, it did not make headline news. In fact, over the next few weeks, it did not make…

Asharq Al-Awsat · Jul 18, 2022

3 Reason Why This Analyst Says CRISPR Therapeutics Is A Biotech Winner

CRISPR Therapeutics AG (NASDAQ: CRSP) has a diversified pipeline with potential CTX001 commercialization and CTX110 potential approval expected in 2024, according to BMO Capital Markets.

Benzinga · Jun 17, 2022

Analyst Ratings for CRISPR Therapeutics

CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings within the last quarter:

Benzinga · Jun 13, 2022

$100 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth This Much

CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 13.5% on an annualized basis producing an average annual return of 25.08%. Currently, CRISPR Therapeutics has a market capitalization of $4.02 billion.

Benzinga · May 2, 2022

Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022

 

Benzinga · Apr 28, 2022

What 4 Analyst Ratings Have To Say About CRISPR Therapeutics

Within the last quarter, CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings:

Benzinga · Apr 28, 2022

$1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth This Much

CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 14.85% on an annualized basis producing an average annual return of 28.2%. Currently, CRISPR Therapeutics has a market capitalization of $4.51 billion.

Benzinga · Apr 20, 2022

Here's How Much $1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today

CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 12.09% on an annualized basis producing an average annual return of 26.02%. Currently, CRISPR Therapeutics has a market capitalization of $5.12 billion.

Benzinga · Apr 1, 2022